Mereo BioPharma Group plc
Mereo BioPharma Group plc is a biopharmaceutical company focused on developing late-stage therapies for rare diseases. Its pipeline centers on setrusumab for osteogenesis imperfecta, alvelestat for severe alpha-1 antitrypsin deficiency-associated lung disease, and a partnered early-stage bone disease program, with development funded through collaborations, licensing, and equity financing.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueLate-stage and early-stage drug candidates being developed for orphan and rare indications.
Bone-disease asset for osteogenesis imperfecta with multiple regulatory designations.
Candidate for severe alpha-1 antitrypsin deficiency-associated lung disease.
Programs monetized through collaborations, milestones, and regional rights retention.
Customers
Mereo does not sell approved commercial products; its economic counterparties are pharmaceutical partners, licensees, investigators, and patient organizations. In rare diseases, the eventual end users are small patient populations treated at specialized centers, which supports a targeted commercial model if programs are approved. Current revenue is driven by collaboration milestones rather than product sales.
Companies that license assets or share development costs and pay milestones, such as ReproNovo and Ultragenyx.
Small, concentrated patient populations treated at specialized sites for OI, AATD-LD, and bone disease.
Physicians and trial sites that enroll patients, generate data, and support regulatory pathways.
Organizations that help with awareness, trial recruitment, and disease education in rare indications.
Strategy
Mereo’s strategy is to acquire de-risked, data-rich rare-disease assets from larger pharma or biotech companies and advance them through late-stage development. The company also uses partnerships and licensing to fund development, preserve capital, and retain selective commercial rights in attractive geographies. Its near-term focus is on regulatory progress, manufacturing readiness, and preparation for possible commercialization of setrusumab and alvelestat.
It is the most advanced rare-disease asset and a potential commercial anchor.
It broadens the pipeline into another orphan indication and diversifies value creation.
Milestones and out-licensing help fund operations without relying only on equity.
Geography
Mereo is operationally international, with development and partnering activity spanning the U.S., Europe, and the U.K. Its rare-disease programs rely on specialized sites in key markets, and the company retains European commercial rights for vantictumab while preparing potential commercialization for setrusumab in Europe and the U.K. Foreign currency movements also matter because the company reports meaningful translation and transaction effects.
Risks
Mereo is still a development-stage biotech with no approved product sales, so its value depends on clinical success, regulatory outcomes, and access to capital. The business is also exposed to foreign exchange volatility, partner execution risk, and the possibility that rare-disease commercialization proves slower or more expensive than expected. Like other biopharma companies, it faces trial failure, safety, manufacturing, and reimbursement risks.
Pipeline value depends on successful late-stage data for setrusumab and alvelestat.
Exposure: Lead rare-disease programs
The company expects to need additional external funding before commercialization.
Exposure: Operations into 2027 and beyond
The company reported significant foreign currency transaction losses and translation gains/losses.
Exposure: International operations and cash balances
Milestones and development progress depend on third-party partners and licensees.
Accounting
Judgemental itemsRevenue is recognized when clinical milestones are achieved, making results episodic.
Impact: The $0.5 million ReproNovo milestone drove all reported revenue in the period.
International operations and cash balances create FX gains/losses that can swing net income.
Impact: Foreign currency transaction losses were a major driver of period net loss.
Derivative-like warrant liabilities are remeasured through earnings.
Impact: Changes in fair value can materially affect reported profit or loss.
Tax credits offset research spending and affect the reported loss profile.
Impact: Credits reduce net loss and can distort comparability across periods.
Similar listed companies
Publicly listed companies with a comparable business focus.
Geron Corporation
GERN · Pharmaceutical Preparations
Geron Corp is a U.S.-based biopharmaceutical company focused on developing and commercializing imetelstat, marketed as RYTELO, for patients with lower-risk myelodysplastic syndromes.
Aptevo Therapeutics Inc.
APVO · Pharmaceutical Preparations
Cero Therapeutics Holdings, Inc.
CERO · Biological Products, (No Diagnostic Substances)
Karyopharm Therapeutics Inc.
KPTI · Pharmaceutical Preparations
Spero Therapeutics, Inc.
SPRO · Pharmaceutical Preparations
Medivir
MVIR · Health Care
Medivir AB is a Swedish pharmaceutical company focused on the development of innovative treatments for serious diseases.
Last updated: 28/04/2026